Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021:25:e01245.
doi: 10.1016/j.idcr.2021.e01245. Epub 2021 Aug 4.

Immune thrombocytopenia associated with Pfizer-BioNTech's BNT162b2 mRNA COVID-19 vaccine

Hiroaki Akiyama  1 , Seiji Kakiuchi  1 , Junpei Rikitake  1 , Hiroyuki Matsuba  1 , Daisuke Sekinada  1 , Yoko Kozuki  1 , Nobuko Iwata  1
Affiliations
Case Reports

Immune thrombocytopenia associated with Pfizer-BioNTech's BNT162b2 mRNA COVID-19 vaccine

Hiroaki Akiyama et al. IDCases. 2021.

Abstract

The recent global pandemic of coronavirus disease 2019 (COVID-19) has led to vaccination in many parts of the world for herd immunity, and as vaccination has progressed, several rare adverse events have been reported. Immune thrombocytopenia (ITP) has been reported to be one of the rare adverse events caused by vaccination with MMR (measles-mumps-rubella) vaccine and influenza vaccine. In addition, ITP has been reported to occur in a small number of cases associated with the COVID-19 messenger ribonucleic acid (mRNA) vaccine. However, there are few reports on the details of the treatment and clinical course; optimal treatment has not yet been established. We report the case of a 20-year-old woman who developed ITP after receiving Pfizer-BioNTech's BNT162b2 vaccine. She had generalized subcutaneous hemorrhage, 14 days after vaccination. At the time of our visit, she had marked thrombocytopenia and intraoral bleeding; she was diagnosed with ITP. Treatment with oral steroids was started and the platelet count promptly improved after 4 days of treatment. Since the response to treatment was very good, we tapered off the steroids. As these vaccines will be increasingly used in the future, it is important to recognize ITP as a possible adverse event.

Keywords: BNT162b; COVID-19 vaccine; Immune thrombocytopenia; Steroids.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Purpuric lesions on the patient’s lower legs.
See this image and copyright information in PMC

References

    1. Cines D.B., Bussel J.B., Liebman H.A., Luning Prak E.T. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113:6511–6521. - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Fueyo-Rodriguez O., Valente-Acosta B., Jimenez-Soto R., Neme-Yunes Y., Inclán-Alarcón S.I., Trejo-Gonzalez R. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination. BMJ Case Rep. 2021;14:14. - PMC - PubMed
    1. Ganzel C., Ben-Chetrit E. Immune thrombocytopenia following the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. Isr Med Assoc J. 2021;23:341. - PubMed

Publication types